Back

The impact of spironolactone in heart failure with mid-range ejection fraction: a future therapeutic tool?

3 March 2019 (09:00 - 17:30)
Organised by:
Congress Presentation Part of: Poster Session 2 - Acute Heart Failure: Pharmacotherapy Pharmacotherapy ACVC Premium Access Acute Cardiovascular Care 2019

About the speaker

Photo
Doctor Maria Ines Pires

Hospital Sao Teotonio, Viseu (Portugal)

3 More presentations in this session

Presentation thumbnail
Doctor Y. Suzuki (Nagakute-cho, JP)
Presentation thumbnail
Doctor M. Corbi Pascual (Albacete, ES)
Abstract
Presentation thumbnail
Mr J. Lopes (Coimbra, PT)
Abstract Slides

Access the full session

Session thumbnail
Poster Session 2 - Acute Heart Failure: Pharmacotherapy

The Event

Event poster

Acute Cardiovascular Care 2019

3 March 2019 09:00 CET
You may be interested in
thumbnail
Congress Presentation
The mineralocorticoid receptor antagonists in heart failure with preserved ejection fraction
29 June 2021
thumbnail
Congress Presentation
Adverse effects of spironolactone in long-term treatment of resistant arterial hypertension
1 September 2019
thumbnail
Congress Presentation
Ferric carboximaltose treatment could also be helpful and safe in heart failure patients with a mid-range ejection fraction.
29 June 2021
thumbnail
Congress Presentation
Optimizing spironolactone dosing for initial treatment success in acute decompensated heart failure: a comparative efficacy study
21 March 2026

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources